Literature DB >> 9140670

Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine.

I Sheiban1, S Tonni, A Chizzoni, A Marini, G Trevi.   

Abstract

The purpose of the present study was to test whether the administration of a vascular-selective organic calcium antagonist (nisoldipine) at the onset of early mechanical reperfusion (by coronary angioplasty) in acute myocardial infarction could prevent or attenuate postischemic stunning and enhance the recovery of left ventricular function in these patients. The study included 36 patients with anterior acute myocardial infarction who underwent an early and successful primary coronary angioplasty within 3 hours of the onset of chest pain (mean time to reperfusion = 113 +/- 37 minutes). The infarct-related artery was the left anterior descending artery in all patients. All had single-vessel disease. Baseline coronary arteriography was completed by left ventriculography. When the infarct-related artery was identified, a guidewire was placed into the target vessel and a balloon catheter was positioned in the artery. At this point all patients were administered 0.8 mg of intracoronary nitrates through the guiding catheter. Patients were then randomized. Seventeen patients (the NIT group) did not receive further treatment during the procedure, while the other 19 patients (the NIS group) received an additional 0.05 mg of intracoronary nisoldipine. Postprocedure treatment consisted of oral nitrates (80-120 mg/day) plus enalapril (10-20 mg/day) in the NIT group patients, and oral nisoldipine (20 mg/day) plus enalapril (10-20 mg/day) in the NIS group patients. The same treatment was maintained during the 6-month follow-up period. An echocardiographic study was performed at 1, 7, 30, 90, and 180 days following the procedure. Left ventriculography and coronary angiography were repeated at 1 and 180 days after the mechanical reperfusion. An exercise test was performed at 30, 90, and 180 days following primary angioplasty. Left ventriculograms and two-dimensional echocardiograms were analyzed by a computerized system that evaluated left ventricular volumes, ejection fraction, segmental wall motion, and diastolic function (from the left ventricular volume curve). Under baseline conditions, the clinical and angiographic characteristics of the patients were similar in both treatment groups. The results showed a significantly earlier recovery of left ventricular systolic and diastolic function in the NIS group patients compared with those of the NIT group. Also, exercise capacity was significantly better at 30 days in the NIS group. The findings of the present study provide further evidence that early reperfusion in acute myocardial infarction is likely to be followed by myocardial stunning. The vascular-selective organic calcium antagonist nisoldipine, administered at the onset of reperfusion, seems to attenuate postischemic stunning and to enhance the recovery of left ventricular function in this clinical subset.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140670     DOI: 10.1023/a:1007713118941

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  4 in total

Review 1.  Calcium antagonists in the post-myocardial infarction setting.

Authors:  B D Bertolet
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

Review 2.  Targeting calcium transport in ischaemic heart disease.

Authors:  M A Hassan Talukder; Jay L Zweier; Muthu Periasamy
Journal:  Cardiovasc Res       Date:  2009-07-29       Impact factor: 10.787

Review 3.  Glutathionylation of the L-type Ca2+ channel in oxidative stress-induced pathology of the heart.

Authors:  Victoria P A Johnstone; Livia C Hool
Journal:  Int J Mol Sci       Date:  2014-10-22       Impact factor: 5.923

Review 4.  Roles of Calcium Regulating MicroRNAs in Cardiac Ischemia-Reperfusion Injury.

Authors:  Eunhyun Choi; Min-Ji Cha; Ki-Chul Hwang
Journal:  Cells       Date:  2014-09-11       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.